In mouse models of colitis, the administration of GLP-1 has been reported to alleviate colonic inflammation and colon damage by reducing the expression of pro-inflammatory cytokine IL-1β, increasing goblet cell numbers, preserving intestinal epithelial architecture, and expanding intestinal crypts [85,149,150]. The gene discussed is IL1B; the disease is colitis.